Lipoprotein(a) mass: a massively misunderstood metric.

Autor: McConnell JP; Health Diagnostic Laboratory, Inc., Richmond, VA., Guadagno PA; Health Diagnostic Laboratory, Inc., Richmond, VA., Dayspring TD; Foundation for Health Improvement and Technology, Richmond, VA., Hoefner DM; Health Diagnostic Laboratory, Inc., Richmond, VA., Thiselton DL; Health Diagnostic Laboratory, Inc., Richmond, VA., Warnick GR; Health Diagnostic Laboratory, Inc., Richmond, VA., Harris WS; Health Diagnostic Laboratory, Inc., Richmond, VA. Electronic address: bharris@hdlabinc.com.
Jazyk: angličtina
Zdroj: Journal of clinical lipidology [J Clin Lipidol] 2014 Nov-Dec; Vol. 8 (6), pp. 550-553. Date of Electronic Publication: 2014 Aug 19.
DOI: 10.1016/j.jacl.2014.08.003
Abstrakt: The importance of lipoprotein (a)-Lp(a)-as a cardiovascular (CV) risk marker has been underscored by recent findings that CV risk is directly related to baseline Lp(a) levels, even in well-treated patients. Although there is currently little that can be done pharmacologically to lower Lp(a) levels, knowledge of its serum concentration is important in overall risk assessment. This review focuses on 1 aspect of Lp(a) that is rarely discussed directly: how to express its levels in serum. There is considerable confusion on this point, and a fuller understanding of what the concentration units mean will help improve study-to-study comparisons and thereby advance our understanding of the pathobiology of this lipoprotein particle. As discussed here, the term Lp(a) mass refers to the entire mass of the particle: lipids, proteins, and carbohydrates combined. At present, there are no commercially available assays that are completely insensitive to the variability in particle mass, which arises not only from differences in apo(a) isoform mass but also from variations in lipid mass. Because lipoprotein "particle number" (molar concentration) has been found to be superior to component-based metrics (ie, low-density lipoprotein particle vs cholesterol concentrations) for CV disease risk prediction, the development of a mass-insensitive Lp(a) assay should be a high priority.
(Copyright © 2014 National Lipid Association. Published by Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: